NYKODE THERAPEUTICS ASA (NYKD.OL) Forecast, Price Target & Analyst Ratings
OSL:NYKD • NO0010714785
3.166 NOK
-0.17 (-5.21%)
Last: Mar 6, 2026, 07:00 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NYKODE THERAPEUTICS ASA (NYKD.OL).
Forecast Snapshot
Consensus Price Target
NOK4.59
+ 44.98% Upside
Next Earnings Forecast
Release DateMay 28, 2026
ChartMill Buy Consensus
42.22%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
NOK4.59
Upside
+ 44.98%
From current price of NOK3.17 to mean target of NOK4.59, Based on 9 analyst forecasts
Low
NOK4.55
Median
NOK4.59
High
NOK4.73
Price Target Revisions
1 Month
104.55%
3 Months
-12.62%
Price Target Summary
9 analysts have analysed NYKD.OL and the average price target is 4.59 NOK. This implies a price increase of 44.98% is expected in the next year compared to the current price of 3.166.
The average price target has been revised downward by 12.62% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
42.22%
NYKD.OL was analyzed by 9 analysts. The buy percentage consensus is at 42. So analysts seem to be rather negative about NYKD.OL.
In the previous month the buy percentage consensus was at a similar level.
NYKD.OL was analyzed by 9 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 28, 2026
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 7.168M -78.89% | 12.902M 79.99% | 8.679M -32.73% | 1.02M | -100.00% | 17.85M | 4.217M -76.38% | 705.78M 16,636.54% | 2.537B 259.46% | 5.998B 136.42% | |
| EBITDA YoY % growth | -48.85M -598.76% | -54.237M -11.03% | -44.88M 17.25% | -29.07M | -26.52M 8.77% | -8.67M 67.31% | -177.091M -1,942.57% | -596.779M -236.99% | 942.33M 257.90% | 2.647B 180.90% | |
| EBIT YoY % growth | -50.664M -555.84% | -56.359M -11.24% | -47.131M 16.37% | -29.07M | -27.03M 7.02% | -10.71M 60.38% | -265.637M -2,380.27% | -668.349M -151.60% | -35.235M 94.73% | 2.555B 7,351.41% | |
| Operating Margin | -706.81% | -436.82% | -543.05% | -2,850.00% | N/A | -60.00% | -6,299.18% | -94.70% | -1.39% | 42.60% | |
| EPS YoY % growth | N/A -1,364.33% | -0.12 19.66% | -0.12 -0.18% | -0.04 | -0.07 -100.00% | -0.06 14.29% | -1.05 -1,622.50% | -1.54 -46.19% | -0.11 92.86% | 3.78 3,536.70% |
Reported data in USD, estimates in NOK
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
14.21%
EPS Next 5 Year
-66.63%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
68.11%
Revenue Next 5 Year
184.95%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
22.69%
EBIT Next 5 Year
-60.17%
NYKODE THERAPEUTICS ASA / NYKD.OL Forecast FAQ
What is the average price target for NYKODE THERAPEUTICS ASA (NYKD.OL) stock?
9 analysts have analysed NYKD.OL and the average price target is 4.59 NOK. This implies a price increase of 44.98% is expected in the next year compared to the current price of 3.166.
When does NYKODE THERAPEUTICS ASA (NYKD.OL) report earnings?
NYKODE THERAPEUTICS ASA (NYKD.OL) will report earnings on 2026-05-28.
What is the expected long term growth rate for NYKODE THERAPEUTICS ASA (NYKD.OL)?
The expected long term growth rate for NYKODE THERAPEUTICS ASA (NYKD.OL) is 68.11%.